While Arcturus Therapeutics Holdings Inc has underperformed by -2.99%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARCT fell by -25.34%, with highs and lows ranging from $25.88 to $8.04, whereas the simple moving average fell by -15.91% in the last 200 days.
On May 28, 2025, Scotiabank started tracking Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) recommending Sector Outperform. A report published by BTIG Research on January 28, 2025, Initiated its previous ‘Buy’ rating for ARCT. Leerink Partners also rated ARCT shares as ‘Outperform’, setting a target price of $70 on the company’s shares in an initiating report dated August 12, 2024. Canaccord Genuity Initiated an Buy rating on December 13, 2023, and assigned a price target of $90. William Blair initiated its ‘Outperform’ rating for ARCT, as published in its report on July 24, 2023. H.C. Wainwright’s report from May 11, 2023 suggests a price prediction of $51 for ARCT shares, giving the stock a ‘Buy’ rating. Wells Fargo also rated the stock as ‘Overweight’.
Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
Further, the quarter-over-quarter decrease in sales is -21.84%, showing a negative trend in the upcoming months.
One of the most important indicators of Arcturus Therapeutics Holdings Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -27.40% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.64, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and ARCT is recording 451.53K average volume. On a monthly basis, the volatility of the stock is set at 6.80%, whereas on a weekly basis, it is put at 7.70%, with a loss of -17.99% over the past seven days. Furthermore, long-term investors anticipate a median target price of $53.50, showing growth from the present price of $12.67, which can serve as yet another indication of whether ARCT is worth investing in or should be passed over.
How Do You Analyze Arcturus Therapeutics Holdings Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 8.44%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 91.87% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ARCT shares are owned by institutional investors to the tune of 91.87% at present.
